Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab. by Kowalczyk-Quintas, C. et al.
ORIGINAL RESEARCH
published: 20 November 2018
doi: 10.3389/fimmu.2018.02698
Frontiers in Immunology | www.frontiersin.org 1 November 2018 | Volume 9 | Article 2698
Edited by:
Hermann Eibel,
Universitätsklinikum Freiburg,
Germany
Reviewed by:
Kang Chen,
Wayne State University, United States
Kathrin De La Rosa,
Helmholtz-Gemeinschaft Deutscher
Forschungszentren (HZ), Germany
*Correspondence:
Pascal Schneider
pascal.schneider@unil.ch
Specialty section:
This article was submitted to
B Cell Biology,
a section of the journal
Frontiers in Immunology
Received: 01 May 2018
Accepted: 01 November 2018
Published: 20 November 2018
Citation:
Kowalczyk-Quintas C, Chevalley D,
Willen L, Jandus C, Vigolo M and
Schneider P (2018) Inhibition of
Membrane-Bound BAFF by the
Anti-BAFF Antibody Belimumab.
Front. Immunol. 9:2698.
doi: 10.3389/fimmu.2018.02698
Inhibition of Membrane-Bound BAFF
by the Anti-BAFF Antibody
Belimumab
Christine Kowalczyk-Quintas 1, Dehlia Chevalley 1, Laure Willen 1, Camilla Jandus 2,
Michele Vigolo 1 and Pascal Schneider 1*
1Department of Biochemistry, University of Lausanne, Lausanne, Switzerland, 2Department of Oncology UNIL CHUV,
University of Lausanne, Lausanne, Switzerland
B cell activating factor of the TNF family (BAFF, also known as BLyS), a cytokine that
regulates homeostasis of peripheral B cells, is elevated in the circulation of patients with
autoimmune diseases such as systemic lupus erythematosus (SLE). BAFF is synthetized
as amembrane-bound protein that can be processed to a soluble form after cleavage at a
furin consensus sequence, a site that in principle can be recognized by any of the several
proteases of the pro-protein convertase family. Belimumab is a human antibody approved
for the treatment of SLE, often cited as specific for the soluble form of BAFF. Here we
show in different experimental systems, including in a monocytic cell line (U937) that
naturally expresses BAFF, that belimumab binds to membrane-bound BAFF with similar
EC50 as the positive control atacicept, which is a decoy receptor for both BAFF and
the related cytokine APRIL (a proliferation inducing ligand). In U937 cells, binding of both
reagents was only detectable in furin-deficient U937 cells, showing that furin is the main
BAFF processing protease in these cells. In CHO cells expressing membrane-bound
BAFF lacking the stalk region, belimumab inhibited the activity of membrane-bound BAFF
less efficiently than atacicept, while in furin-deficient U937 cells, belimumab inhibited
membrane-bound BAFF and residual soluble BAFF as efficiently as atacicept. These
reagents did not activate complement or antibody-dependent cell cytotoxicity upon
binding to membrane-bound BAFF in vitro. In conclusion, our data show that belimumab
can inhibit membrane-bound BAFF, and that BAFF in U937 cells is processed by furin.
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INTRODUCTION
BAFF and APRIL are important fitness and survival factors for B cells and plasma cells in
the periphery. They exert their function through different receptors: BAFFR (BAFF receptor,
TNFRSF13A) that binds to BAFF only, TACI (transmembrane activator and calcium modulator
and cyclophilin ligand interactor, TNFRSF13B) that binds to BAFF and APRIL, and BCMA (B cell
maturation antigen, TNFRSF17) that also binds to BAFF and APRIL [reviewed in (1)]. BAFFR
transduces BAFF survival signals in transitional and naïve B cells, both of which are greatly
decreased in BAFF-ko and BAFFR-ko mice (2–5). TACI and BCMA are expressed either upon
B cell activation and/or at later stages of B cell differentiation. For example, BCMA is expressed
in plasma cells that can use APRIL and/or BAFF for survival (6). Although BAFF is synthetized
as a membrane-bound protein, it can be processed to a soluble form by cleavage at a furin
consensus-processing site (7, 8). Furin belongs to the substilisin/kexin-like pro-protein convertase
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(PCSK) family of proteases, seven of which (PCSK1-2, furin
and PCSK4-7) have arginines in their recognition sequences,
and most of which are ubiquitously expressed. They are often
redundant for substrate cleavage and they process a vast panel of
targets, among others hormones, enzymes, receptors, cytokines
and extracellular matrix components [reviewed in (9)]. With
regard to BAFF, circulating levels are found elevated in diseases
with involvement of auto-reactive B cells, including systemic
lupus erythematosus (SLE) [reviewed in (10, 11)]. Belimumab,
a human monoclonal IgG1λ anti-BAFF antibody approved by
the FDA, can improve the condition of SLE patients (12, 13).
Belimumab is specific for BAFF, and is more precisely described
as an inhibitor of soluble BAFF (14, 15). Atacicept is another
BAFF inhibitor consisting of the ligand-binding portion of
the receptor TACI fused to a modified Fc portion of human
IgG1 to remove binding to Fc receptors and to complement.
Atacicept is characterized by a broader specificity of inhibition
that includes APRIL and heteromers of BAFF and APRIL (16).
Atacicept is under clinical development, also for the treatment
of SLE (17). Here, we genetically inactivated furin in U937
histiocytic lymphoma cells that naturally express BAFF (18) to
convert these cells form BAFF shedding into membrane-bound
BAFF-expressing cells, indicating that furin itself is the main
BAFF-processing protease in these cells. Membrane-bound BAFF
on furin-deficient U937 was bound and inhibited by belimumab,
suggesting that belimumab targets membrane-bound in addition
to soluble BAFF.
MATERIALS AND METHODS
Proteins and Antibodies
Belimumab (registered trade name Benlysta), denosumab
(registered trade name Xgeva), adalimumab (registered trade
name Humira), and human IgG (intraveinous immunoglobulins;
registered trade name Kiovig) were purchased from the
Pharmacy of Lausanne University Hospital (CHUV). Atacicept
was kindly provided by Henry Hess (Merck KGaA). BCMA-
Fc and Fc-BAFF were produced in CHO cells and affinity
purified on Protein A-Sepharose, essentially as described (19).
When indicated, dimeric BCMA-Fc was used. Dimeric BCMA-
Fc was obtained as a defined peak after size fractionated by
gel filtration on a Superdex 200 Increase 10/30 column (GE
Healthcare) equilibrated in PBS. BCMA-COMP-Flag (20) was
produced by transient transfection of HEK 293T cells with
the polyethyleneimide method (21). 7-day-old conditioned cell
supernatants in serum-free OptiMEM medium were collected
and used directly.
Cell Lines
HEK 293T and histiocytic lymphoma U937 cells were obtained
form late Jürg Tschopp (University of Lausanne). CHO-
S cells were from Thermoscientific (A1155701). CHO-3296
clone 7 expressing uncleavable BAFF (hBAFF 185-136) was
Abbreviations: BAFF, B cell activating factor of the TNF family; APRIL, A
proliferation-inducing ligand; BAFFR, BAFF receptor; TACI, Transmembrane
activator and CAML interactor; BCMA, B cell maturation antigen; SLE, systemic
lupus erythematosus.
obtained by transfection with polyethyleneimide, selection
for 3 passages in 500µg/ml of G418 sulfate (Calbiochem,
345812) and cloning by limiting dilution. Clones were screened
for BAFF expression by staining with atacicept by flow
cytometry (see “Flow cytometry”). U937 cell deficient for
BAFF (U937-3515 clone B9) and U937 cells deficient for
furin (U937-3511 clone D3) were generated by lentiviral
transduction of CRISPR/Cas9-expression vectors with hBAFF
gRNA, respectively hFurin gRNA (Supplementary Table 1).
Annealed oligonucleotides 5
′
- CACCGACTGATAAGACCT
ACGCCAT-3
′
and 5
′
- AAACATGGCCGTAGGTCTTATCAGT-
3
′
(for hBAFF) or 5
′
- CACCGAAGTGCACGGAGTCTCACA
C-3
′
and 5
′
- AAACGTGTGAGACTCCGTGCACTTC-3
′
(for
hFurin) were cloned in the BsmBI restriction site of lentrcrispr
v2 plasmid (Addgene #52961) (22). These plasmids were co-
transfected with co-vectors pCMV-VSV-g (Addgene #8454) and
psPAX2 (Addgene #12260) (Supplementary Table 1) into 293T
cells with polyethyleneimide. The next day, cells were washed
with PBS and cultured for an additional day in RPMI 10% FCS.
Cell supernatants filtered at 0.45µm were supplemented with
8µg/ml polybrene (Sigma, H9268) and 2.5ml were added to 2×
106 pelleted U937 cells that were subsequently cultured overnight
in a 12-well plate, then washed and expanded for 3 days in a
6-well plate in RPMI 10% FCS. Cells were then selected for 3
days in RPMI 10% FCS, 1µg/ml puromycin (EnzoLifeSciences
ALX 380-028). Surviving cells were cloned in RPMI 10% FCS,
in culture plates pre-coated for 5min at 37◦C with 1µg/ml of
poly-lysine (Sigma P6407) in water. Furin-deficient clones and
BAFF-deficient clones were identified by their impairment to
release active soluble BAFF in their supernatants (see “Cytotoxic
assays”). Jurkat JOM2 BAFFR:Fas-2308 cl21 reporter cells were as
described (16, 23, 24). Jurkat cells expressing FcγRIIIa andNFAT-
driven luciferase were provided in the ADCC reporter bioassay
core kit (Promega, G7010) and used as recommended by the
manufacturer.
Biotinylations
Onemilligram of belimumab or 1mg of atacicept in 1ml of 0.1M
Na-borate pH 8.8 were biotinylated for 2 h at room temperature
with 10 µl of EZ-LinkTm sulfo-N-hydroxysuccinimide-LC-
biotin (Pierce, #21335) at 30µg/ml in DMSO. Reaction was
terminated by addition of 30 µl of 1M NH4Cl, and buffer
was exchanged to PBS using a 30 kDa cutoff centrifugal
device.
CFSE Labeling
Carboxyfluorescein-succinimidyl ester (CFSE, Sigma 21888) at
10mM in dimethylsulfoxide was stored at −70◦C until use.
BAFFR:Fas reporter cells (∼107) were labeled by incubation
for 8min at 37◦C in a freshly prepared mixture of PBS, 1%
FCS and 2µM CFSE, or in PBS, 0.1µM CFSE. Reactions were
quenched by the addition of RPMI 10% FCS, cells were harvested,
washed twice with RPMI 10% FCS and used to assay membrane-
bound BAFF (see “Cytotoxic assays with BAFFR:Fas reporter
cells”).
Frontiers in Immunology | www.frontiersin.org 2 November 2018 | Volume 9 | Article 2698
Kowalczyk-Quintas et al. Belimumab Inhibits Membrane-Bound BAFF
Cytotoxic Assays With BAFFR:Fas
Reporter Cells
Recombinant Fc-hBAFF was used at the indicated
concentrations, and BAFF in conditioned medium of CHO
or U937 cells (parental or stable clones) was used at the
indicated dilutions of supernatants. Inhibitors, when present,
were used at the indicated concentrations and pre-incubated
for at least 3min with effectors in 50 µl of RPMI 10% FCS.
Unlabeled Jurkat JOM2 BAFFR:Fas-2308 clone 21 reporter cells
(20,000–50,000/well) were added in 50 µl of RPMI 10% FCS
and incubated overnight (∼16 h) at 37◦C, 5% CO2. Cell viability
was then recorded by addition of 20 µl of PMS/MTS (phenazine
methosulfate at 45µg/ml and 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium at 2
mg/ml in PBS) and by monitoring absorbance at 492 nm after
adequate color development (∼2–8 h) (24).
Themeasure ofmembrane-bound BAFF activity onU937 cells
was performed in 96 well plates, in a final volume of 100 µl of
RPMI 10% FCS, at 37◦C and with 5% CO2. 50 µl of effector
cells (U937-3515 clone B9 or U937-3511 clone D3, 105 cells), or
50 µl of soluble effectors (Fc-hBAFF at 100 ng/ml) were mixed
with 20 µl of 5-fold concentrated inhibitors for 6 h, then 30 µl of
CFSE-labeled BAFFR:Fas reporter cells (∼5 × 104) were added
for an additional 11 h. Cells were transferred on ice in 1ml tubes
containing 10 µl of 10µg/ml propidium iodide, and analyzed by
flow cytometry (See “Flow cytometry”).
For the measure of membrane-bound BAFF on CHO-
3296 cl7 cells, experiments were performed in 48 well plates.
Untransfected CHO cells, or CHO-3296 cl7 cells (1.5× 105/well)
were left to adhere for 2 h, after which timemediumwas removed
and replaced by 200 µl of fresh medium. Wells without CHO
cells contained medium only. Hundred µl of inhibitors (at 5-fold
the final desired concentration), 50 µl of Fc-BAFF at 1µg/ml
(or 50 µl of medium in conditions without Fc-BAFF) and 150
µl of CFSE-labeled BAFFR:Fas reporter cells (∼2.5 × 105 cells)
were added and incubated for 11 h. Non adherent cells were
transferred into 4ml tubes, and then pooled with adherent cells
detached with trypsin-EDTA. Cells were spun for 1min at 5,000
rpm (2,400 × g), pellets were suspended in 100 µl of PBS, 5%
FCS and supplemented with 10 µl of 10µg/ml propidium iodide
before analysis (See “Flow cytometry”).
Flow Cytometry
293T cells were co-transfected with hBAFF expression vectors
and an EGFP expression vector as a tracer. Cells were
stained 3 days later with the indicated amounts of atacicept
FIGURE 1 | Belimumab binding to BAFF on transfected 293T cells prevents concomitant binding of BCMA. (A) 293T cells transiently transfected with plasmids
coding for full length BAFF wild type (BAFF full), full length BAFF with mutated furin site (BAFF 1FS), full length BAFF deleted for the stalk region and furin site (BAFF
1stalk) or with empty plasmid (Mock) were stained with the indicated amounts of belimumab or atacicept, or denosumab as control. Mean fluorescence intensity (MFI)
of staining (in the phycoerythrin chanel) was monitored for cells expressing medium levels of co-transfected EGFP (2 × 105 to 6 × 105 fluorescence units). Mean ±
SEM of triplicate measures (note that error bars are smaller than symbols). Experiment performed 5 times (twice in monoplicates, without BAFF 1stalk and
denosumab controls). (B) 293T cells transfected as indicated (transfection distinct from that of panel A) were pre-incubated with buffer (none), atacicept (ata),
belimumab (beli) or denosumab (deno) and then stained with BCMA-COMP-Flag and anti-Flag secondary reagents. Mean fluorescence intensity (MFI) was measured
as in panel A. Mean ± SEM of triplicate measures. Experiment performed 3 times (once in monoplicate, without denosumab control).
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or belimumab in 50 µl of PBS, 5% FCS for 20min on
ice, followed by phycoerythrin-coupled rat anti-human IgG
(Southern Biotech Associate, 2040-09, 1/500). Alternatively,
transfected cells were pre-incubated with 5 µg of atacicept
or belimumab in 25 µl of PBS 5% FCS for 20min on
ice, then stained for 20min, without wash, by addition
of 25 µl of BCMA-COMP-Flag in conditioned OptiMEM
supernatants, followed by biotinylated anti-FLAG (Sigma, F9291,
1/500) and phycoerythrin-coupled streptavidin (eBioSciences,
12-4317-87, 1/500). Data was acquired with an AccuriC6 flow
cytometer (BD Bioscience) and analyzed with the FlowJo
software (TreeStar, Ashland, OR). Mean fluorescence intensity
of atacicept, belimumab or BCMA-COMP-Flag staining was
measured for cells expressing medium levels (2 × 104 to 2 × 105
fluorescence units) of EGFP.
CHO-3296 clone 7 cells were stained with atacicept,
belimumab or denosumab as described for transfected 293T cells,
except that MFI was reported for all live cells. U937 cells (wild
type, furin-deficient or BAFF-deficient) were pre-incubated with
human IVIGs (50 µg in 50 µl of PBS, 5% FCS) for 20min on ice,
washed and stained for 20min on ice with the indicated amount
of biotinylated atacicept or biotinylated belimumab in 50 µl
of PBS 5% FCS followed by phycoerythrin-coupled streptavidin
(1/500).
CFSE-labeled reporter cells (co-cultured with membrane-
bound BAFF-expressing cells, recombinant Fc-BAFF or controls)
were stained with propidium iodide as described (see “Cytotoxic
assays with BAFFR:Fas reporter cells”) and analyzed by flow
cytometry. The proportion of live reporter cells was calculated as
follows: [number of live reporter cells / (number of live reporter
cells + number of dead reporter cells)], where live cells were
CFSE+ PI− cells in the live FCS/SSC gate, and dead cells were all
CFSE+ cells in the dead FCS/SSC gate. This number was divided
by the proportion of live cells in untreated controls to correct for
spontaneous death, and multiplied by 100 to get the percentage
of specific target cell viability.
BAFF ELISA
BAFF in conditioned supernatant of U937 cells was quantified
using the hypersensitive hBAFF ELISA kit (Adipogen, AG-
45B-0001-KI01) according to the manufacturer’s protocol.
Supernatants of BAFF-deficient and furin-deficient cells were
measured in duplicate at a dilution of 1/2, and those of wild type
cells at dilutions of 1/4, 1/40, and 1/400.
Complement Activation Assay
CHO-3296 clone 7 cells or CHO cells (2 × 104/well in 80 µl
of DMEM/F12 (1/1) 2% FCS) were left to adhere overnight in
FIGURE 2 | Belimumab binds and partially inhibits membrane-bound BAFF lacking the stalk region expressed in CHO cells. (A) CHO cells stably expressing
uncleavable BAFF 1stalk were stained with the indicated amounts of atacicept, belimumab or denosumab. Mean fluorescence intensity (MFI) of staining was
monitored. Single measures were performed. Experiment performed 3 times. (B) BAFFR:Fas reporter cells were exposed to titrated amounts of conditioned
supernatants of CHO cells with or without expression of uncleavable BAFF 1stalk, or to recombinant soluble BAFF (Fc-BAFF) added as a positive control. After
overnight incubation, cell viability was monitored with the PMS/MTS test. Mean ± SEM of triplicates. Experiment performed twice. (C) CFSE-labeled BAFFR:Fas
reporter cells were co-cultured with CHO cells expressing uncleavable BAFF in the presence of increasing concentrations of atacicept, belimumab or denosumab. Cell
viability after overnight incubation was measured by flow cytometry. Measures are duplicates (mean ± SEM). Experiment performed twice. (D) Same as panel C,
except that uncleavable BAFF 1stalk cells were replaced by a lethal dose of Fc-BAFF (100 ng/ml). Single measures were performed. Experiment performed twice.
(E) Same as panel C, except that uncleavable BAFF 1stalk cells were replaced by control CHO cells. Single measures were performed. Experiment performed twice.
(F) CFSE-labeled BAFFR:Fas reporter cells were co-cultured overnight with CHO cells and 100 ng/ml of Fc-BAFF, in the presence of inhibitors at the indicated
concentrations. Single measures were performed. Experiment performed twice.
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96-wells culture plates. Fc-containing reagents were then added
in 10 µl of medium, incubated for 10min at room temperature
before addition of 10 µl of untreated or heat-inactivated (30min
at 56◦C) normal human serum (from P.S.) for 2 h at 37◦C. Cell
viability was monitored with PMS/MTS (see “Cytotoxic assays
with BAFFR:Fas reporter cells”).
Antibody-Dependent Cell-Mediated
Cytotoxicity Assay
Antibody-dependent cell-mediated cytotoxicity was measured
using the ADCC core kit (Promega, G7010), according to the
manufacturer’s protocol. CHO-3296 clone 7 cells were used as
targets, adalimumab, atacicept, BCMA-Fc and belimumab at the
indicated concentrations were used as mediators, and Jurkat
cells expressing both human FcγRIIIa V158 and NFAT-induced
luciferase were used as effectors. 25,000 target cells per well were
seeded in 96 wells white plates in 100 µl of DMEM:F12 2% FCS
and left to adhere overnight. Ninety-five microliter of medium
was removed and replaced by 25 µl of RPMI supplemented with
4% of low Ig FCS, 25 µl of the test reagent and 25 µl of freshly
defrosted effector cells. After 6 h of incubation, 75 µl of luciferase
substrate was added and luminescence was monitored 15min
later.
Statistics
Replicate measurements are shown as mean ± SEM. EC50 of
titration curves were determined after normalization of cell
viability using the “non linear regression (curve fit)” followed
by the “log(agonist) vs. normalized response–variable slope”
function of Prism 7 (GraphPad Software).
RESULTS
Belimumab and Atacicept Bind to and
Inhibit BAFF at the Surface of Transfected
293T or CHO Cells
In a FACS-based assay, both atacicept and belimumab stained
293T cells transfected with full length BAFF, but not mock-
transfected cells. BAFF with a mutated furin consensus
sequence (SRNKRAVGP→ SRNKLQGP) (BAFF 1FS) or BAFF
lacking the stalk region linking the transmembrane domain
to the extracellular receptor-binding domain, a deletion that
included the furin consensus sequence (BAFF 1stalk) were also
recognized by atacicept and belimumab, while the unrelated
antibody denosumab stained none of these cells (Figure 1A).
Binding of atacicept or belimumab to membrane-bound BAFF
prevented subsequent binding of recombinant BCMA, one of the
FIGURE 3 | Belimumab binds to membrane-bound BAFF in furin-deficient U937 cells. (A) Wild-type (WT), furin-deficient (furin-ko) and BAFF-deficient (BAFF-ko) U937
cells were stained with the indicated amounts of biotinylated atacicept after saturation of Fc receptors with human IgGs. Mean fluorescence intensity (MFI) of staining
was monitored. Single measures were performed. Experiment performed four times. (B) Same as panel A, except that staining was performed with biotinylated
belimumab. Experiment performed four times. (C) The indicated U937 cells were washed and then put in culture. Human BAFF was quantified by ELISA in
conditioned cell supernatants collected at the indicated time points. LLQ: lower limit of quantification. Double-sided arrows indicate the fold difference between
concentrations of BAFF in supernatants of wild type and furin-deficient U937 cells. Error bars of measures performed in duplicate (mean ± SEM) are smaller than
symbol size. Experiment performed twice. (D) BAFFR:Fas reporter cells were exposed to titrated amounts of the same conditioned supernatants used in panel C.
After an overnight incubation, cell viability was monitored with the PMS/MTS assay. Single measures were performed. Double sided arrows indicate the fold difference
between EC50 of wild type and furin-deficient supernatants. One measure indicated in brackets was excluded for the determination of EC50. Experiment performed
twice in this format, and two more times with a single time point.
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FIGURE 4 | Belimumab inhibits membrane-bound and residual soluble BAFF
in furin-deficient U937 cells. (A,B) CFSE-labeled BAFFR:Fas reporter cells
were exposed to (A) medium or to (B) a lethal dose of Fc-BAFF (50 ng/ml) in
the presence of increasing concentrations of atacicept, belimumab or
denosumab. Cell viability after overnight incubation was measured by flow
cytometry. Mean of triplicates ± SEM. Experiment performed twice. (C,D)
CFSE-labeled BAFFR:Fas reporter cells were co-cultured overnight with (C)
BAFF-deficient (BAFF-ko) or (D) furin-deficient (furin-ko) U937 cells in the
presence of atacicept, belimumab or denosumab at the indicated
concentrations. Mean of triplicates ± SEM. Experiment performed twice. (E)
BAFFR:Fas reporter cells were exposed to undiluted conditioned medium of
the indicated U937 cells that were grown alone, but for the same time (17 h)
and otherwise identical conditions to those of U937 cells used in panels C and
D. Medium and Fc-BAFF at 50 ng/ml in medium pre-incubated alone for 17 h
in the same conditions were used as controls. Viability of reporter cells was
monitored with the PMS/MTS assay. Mean of triplicates ± SEM. Experiment
performed twice.
receptors for BAFF, suggesting that the binding of either atacicept
or belimumab inhibits membrane-bound BAFF (Figure 1B).
In order to measure the activity of membrane-bound BAFF,
we generated a stable clone of CHO cells expressing BAFF1stalk,
i.e., uncleavablemembrane-bound BAFF. These cells stainedwith
both atacicept and belimumab, but not with the control antibody
denosumab (anti-RANKL) (Figure 2A) and did not release
detectable levels of soluble BAFF activity in their supernatants
(Figure 2B). Unlabeled CHO cells expressing uncleavable BAFF
were co-cultured with CFSE-labeled BAFFR:Fas reporter cells.
In reporter cells, the extracellular domain of BAFFR is fused
to the transmembrane and intracellular domains of the death
receptor Fas, so that they are killed upon engagement of
BAFFR, and so that BAFF inhibitors can protect them from
BAFF-mediated killing. CHO cells expressing uncleavable BAFF
readily killed BAFFR:Fas reporter cells, a killing that could
be inhibited in a dose-dependent manner by both atacicept
and belimumab, although atacicept was about 10 times more
efficient than belimumab in this respect (Figure 2C). Reporter
cells also died in response to soluble recombinant BAFF, but
in this case inhibition by atacicept or belimumab was equally
good (Figure 2D). Controls showed that atacicept, belimumab
or untransfected CHO cells had no deleterious effect on reporter
cells (Figure 2E), and that untransfected CHO cells did not
prevent atacicept and belimumab from inhibiting soluble BAFF
(Figure 2F). Taken together, these results show that binding
of atacicept and belimumab to membrane-bound BAFF is
inhibitory.
Processing of Membrane-Bound BAFF to
Active Soluble BAFF Is Mediated by Furin
in U937 Cells
In order to determine the action of atacicept and belimumab on
endogenous BAFF, we used monocytic U937 cells that naturally
produce soluble BAFF (18, 25). Atacicept and belimumab did
not stain wild type and BAFF-deficient U937 cells by flow
cytometry (Figures 3A,B). However, CRISPR/Cas9-mediated
deletion of furin with a construct targeting the active site of the
protease abrogated >98% of the release of both BAFF protein
(Figure 3C) and BAFF activity (Figure 3D) in supernatants
of U937 cells, while increasing cell surface levels of BAFF
that became detectable by staining with both atacicept and
belimumab (Figures 3A,B).
Inhibition of Membrane-Bound BAFF in
U937 Cells by Atacicept and Belimumab
Inhibition of non-mutated membrane-bound BAFF was tested
in furin-deleted U937 cells. Atacicept and belimumab on their
own were not toxic for reporter cells (Figure 4A). On the
contrary, they both protected reporter cells from a lethal
dose of soluble recombinant BAFF at roughly stoichiometric
ratio (Figure 4B). BAFF-deficient U937 cells were harmless
to BAFFR:Fas reporter cells (Figure 4C), but furin-deficient
U937 cells, which express membrane-bound BAFF, efficiently
killed them (Figure 4D). This killing was inhibited in a dose-
dependent manner and with similar efficacy by both atacicept
and belimumab, while the control antibody denosumab did
not protect against membrane-bound BAFF (Figure 4D). An
additional control showed that BAFF released into supernatant
of furin-deficient U937 cells during the 17 h co-culture period
could only kill about 30% of reporter cells (Figure 4E), indicating
that the remaining toxicity of furin-deficient U937 cells on
BAFFR:Fas reporter cells was due to membrane-bound BAFF
(Figure 4D). Taken together, these results indicate that both
endogenous membrane-bound BAFF and residual soluble BAFF
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FIGURE 5 | No detectable effector function of belimumab bound to membrane-bound BAFF. (A) CHO BAFF 1stalk cells or CHO cells were pre-incubated for 30min
with atacicept, belimumab, denosumab, adalimumab, BCMA-Fc or size-fractionated (dimeric) BCMA-Fc at the indicated concentrations, and subsequently exposed
for 2 h to normal human serum that had been heat-inactivated or not. Cells viability was monitored with the PMS/MTS assay. Mean ± SEM of duplicates. Experiment
performed twice (but only once for the condition of dimeric BCMA-Fc). (B) CHO BAFF 1stalk cells were pre-incubated with atacicept, belimumab, BCMA-Fc, or
adalimumab at the indicated concentrations, after which time surrogate effector cells of antibody-dependent cellular-mediated cytotoxicity were added. NFAT-driven
luciferase expression is induced when opsonized IgG-containing molecules engage FcγRIIIa expressed in these reporter cells. Specific signal in relative luminescence
units (RLU) was obtained after subtraction of background of unstimulated cells (∼105 RLU). Mean ± SEM of triplicate measures. Experiment performed twice.
in U937 cells are bound and inhibited by atacicept and
belimumab.
Opsonized Atacicept and Belimumab Do
Not Induce Complement or Cell-Mediated
Toxicity
IgGs that are opsonized on a cell surface activate complement
or antibody-dependent cell-mediated cytotoxicity via their
fragment crystallisable (Fc) regions. Atacicept was used as a
negative control because its mutated Fc region activates neither
of these pathways. Neither atacicept nor belimumab activated
complement when bound to CHO cells expressing uncleavable
BAFF (Figure 5A). In contrast, BCMA-Fc, a BAFF-binding decoy
receptor with a wild type human IgG1 Fc portion, decreased
viability of target cells in the presence of normal human serum,
but not in de-complemented serum and not in CHO cells
expressing no BAFF (Figure 5A). Adalimumab, an anti-TNF
antibody with reported ability to activate complement (26)
had no activity in the absence of its target (Figure 5A). It is
noteworthy that a purely dimeric preparation of BCMA-Fc,
obtained after gel filtration, displayed the same activity as “crude”
BCMA-Fc (Figure 5A).
Antibody-dependent cell-mediated cytotoxicity was
monitored in a surrogate assay in which the activation of
Fcγ receptor IIIa over-expressed in Jurkat T cells drives NFAT
(nuclear factor of activated T cells)-dependent expression of
luciferase. Neither atacicept nor belimumab activated reporter
cells when bound to membrane-bound BAFF on CHO cells,
while the positive control BCMA-Fc did (Figure 5B). We
conclude from these data that atacicept and belimumab inhibit
their target cytokine(s) in soluble or membrane-bound forms,
but do not kill BAFF-expressing cells, at least in vitro.
DISCUSSION
It was previously reported that belimumab inhibits BAFF, but
not APRIL. In addition, belimumab does not inhibit any of
the BAFF-APRIL heteromers, while atacicept inhibits BAFF,
APRIL and heteromers thereof (16). Another difference is that
soluble BAFF can exist as 3-mers, or can assemble as 60-
mers (27). Belimumab cannot inhibit BAFF 60-mers unless they
first dissociate into 3-mers, whereas atacicept and another anti-
BAFF antibody, tabalumab, can inhibit BAFF 60-mers (28–30).
Belimumab is often described in the literature as an inhibitor
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of soluble BAFF. This conclusion probably finds its origin into
the original description of the antibody, where belimumab could
not stain IFNγ-stimulated human monocytes by flow cytometry,
while another antibody called 12D6 could (14). This was later
interpreted as “ [. . . ], belimumab specifically recognizes the
soluble, biologically active form of BLyS” (31). Our present
results question this conclusion and re-enforce previous results
obtained with over-expressed BAFF in CHO cells showing
that belimumab can inhibit membrane-bound BAFF (28). The
monoclonal antibodies 12D6, 2E5, and 9B6 can all stain human
monocytes (7, 14, 18). It would be interesting to monitor their
binding to wild type, furin-deficient and BAFF-deficient U937
cells side by side with belimumab to determine if they are
really better binders of membrane-bound BAFF, or whether there
might be other causes for their binding to monocytes.
It has long been recognized that BAFF is processed at a furin
consensus site (7, 8). Here we provide the first indication that in
U937 cells, BAFF is cleaved by furin, with no or little contribution
of other members of the pro-protein convertase subtilisin/kexin
family. However, we did not investigate whether this is also true
for other cell lines or primary cells. Like Baff -ko mice, mice
with non-cleavable BAFF have few mature B cells, indicating that
membrane-bound BAFF, unlike soluble BAFF, does not support
naïve B cells (32). But when follicular B cells were restored
by administration of recombinant soluble BAFF 3-mer, full
maturation of B cells, measured by CD23 expression, required
membrane-bound BAFF (32). In mice with non-cleavable BAFF,
membrane-bound BAFF co-localized with medullary fibroblastic
reticular cells in lymph nodes. These cells make more direct
contacts with plasma cells than any other cell type, and they
can support survival of plasma cells in vitro, alone or together
with macrophages, while other lymph node cell types cannot
(33). This suggests that membrane-bound BAFF may be more
important for plasma cells than for naïve B cells, possibly through
activation of the receptors TACI and BCMA, and that inhibition
of membrane-bound BAFF might be relevant to the mechanism
of action of belimumab in SLE patients.
In this study, we have observed that belimumab binds
normally to BAFF 1stalk overexpressed in CHO cells but was
less efficient than atacicept to inhibit it. This was however not
the case in furin-deficient U937 cells in which both atacicept
and belimumab similarly inhibited full-length membrane-bound
BAFF (and residual soluble BAFF). Thus, BAFF binding and
BAFF inhibitory activities did not correlate well only for the pair
of belimumab - BAFF1stalk, but not for the pairs belimumab—
full length BAFF, atacicept—BAFF 1stalk or atacicept—full-
length BAFF. How can these results be reconciled in a molecular
model? We have previously observed that atacicept binds and
inhibits BAFF even when it is densely packed as 60-mers (30).
It is therefore not surprising that atacicept can bind and inhibit
membrane-bound BAFF irrespective of the length of the stalk
region, as observed experimentally. We have also observed that,
in contrast to intact belimumab, Fab fragments of belimumab
did not or only very poorly inhibit the activity of BAFF 3-mers,
probably because monovalent Fab can be displaced from BAFF
by BAFFR (30). This would support a hypothetic model in which
the first monovalent binding of belimumab to membrane-bound
BAFF would allow cell staining by flow cytometry but would
FIGURE 6 | Hypothetical model for the binding of belimumab and atacicept to
membrane-bound BAFF. The 66 amino acids-long stalk of BAFF contains the
furin cleavage site and, if linear and extended, could have three times the
height of the globular TNF homology domain. In contrast, the engineered
stalk-less BAFF is much closer to the membrane. Atacicept binds BAFF from
the side opposite to the membrane and has free access regardless of the
length of the stalk. Belimumab is not only bulkier but also binds more on the
side of BAFF along the entire height of the TNF homology domain. The first
binding of belimumab to membrane-bound BAFF is probably always easy, but
insufficient to inhibit the biological activity of BAFF. Inhibition only takes place
upon binding of the second arm of the antibody to membrane-bound BAFF.
Movements of the antibody to reach its second binding site might be
compromised for steric hindrance reasons if BAFF is located too close to the
cell membrane in BAFF 1stalk.
be poorly inhibitory. Membrane-bound BAFF would only be
inhibited upon binding of the second arm of the antibody
that increases binding avidity, preventing efficient displacement
by BAFFR. The molecular “gymnastic” that belimumab must
accomplish to reach its second binding site on membrane-bound
BAFF might be partially impaired for steric hindrance reasons in
the specific case of BAFF 1stalk that is positioned very close to
the cell membrane (Figure 6).
Interestingly, we find that belimumab does not activate
complement and Fc receptors in vitro. If this holds true in
vivo, belimumab should not act by depleting cells expressing
membrane-BAFF, in line with the current view of the mechanism
of action of belimumab.
Belimumab was the first targeted treatment, approved in 2011,
for the treatment of SLE, but its clinical efficacy is limited and
not all patients benefit from treatment; this also holds true for
other BAFF-blocking agents that have been tested in clinical
trials (34). Loss of tolerance and development of auto-immunity
is multifactorial, and SLE likely encompasses a spectrum of
conditions with distinct etiologies that may be more or less
dependent on BAFF (35, 36). This diversity is also reflected
in the various spontaneous or induced mouse models of the
disease (37). Different forms of BAFF and APRIL may trigger
BAFFR, TACI, and BCMA in distinct manners with effects that
could both promote (e.g., stimulation of auto-reactive B cells) or
counteract (e.g., stimulation of regulatory B cells) development
of symptoms. Indeed, in a mouse model of lupus, intricate
positive or negative actions of the different receptors on disease
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severity have been described (38). In this context, it might not be
superfluous to know the fine specificity of belimumab and other
BAFF inhibitors.
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